FDA records identify Sequitur Health Corp. as the applicant on a single 510(k) premarket notification in the collection reviewed here, K260613, received February 25, 2026 and decided September 1, 2026. The submission covers the AMI™ Plasma Cartridge, AMI™ under product code JID, with a Traditional clearance type, a Summary statement and review by the Clinical Chemistry advisory committee. The applicant address in the filing is 6161 E Mayo Blvd., Suite 221d, Phoenix, AZ 85054, which is a filing address rather than a verified headquarters. [1][2]
The documented 510(k) submission
K260613 lists the device name AMI™ Plasma Cartridge, AMI™, product code JID, decision code SESE and decision description Substantially Equivalent, dated September 1, 2026. The record shows a Traditional clearance type, no third-party review, a Summary statement and the Clinical Chemistry advisory committee as both advisory and review committee. The openFDA device fields in the same record describe a photometric method for ammonia, device class 1 and regulation number 862.1065. [1]
The FDA 510(k) Premarket Notification database page for K260613 is the official counterpart to the API record; the retrieved page text consists of navigation and agency boilerplate rather than submission detail. The filing's substantive fields therefore rest on the API record, and no review memorandum, clinical data or labeling content appears in the numbered sources. [2]
Registration and listing records
An FDA.report company page indexes a registration for SEQUITUR HEALTH CORP. under registration and FEI number 3023591031 at 6161 E Mayo Blvd STE 221D, Phoenix, AZ 85054, with an expiration year of 2027 and an initial importer flag of Y. The same page lists a device listing tied to premarket submission K260613 for the AMI™ Plasma Cartridge, AMI™ under product code JID with a decision date of September 1, 2026, plus two additional listing keys without device or product code detail. FDA.report states that it indexes public FDA datasets and legacy records and that critical regulatory decisions should be verified with the official FDA source. [6]
Separate Establishment Registration and Device Listing pages retrieved for product code JJE and for a listing identifier associated with product code JID contain only interface text and agency navigation, with no company-specific listing content. Those pages do not corroborate or contradict the registration details above. [3][5]
Company statements and public funding record
Sequitur Health Corp.'s own website states a mission to improve patient care and quality of life by applying technological breakthroughs to unmet patient and physician needs. The same page lists support from the National Science Foundation, the National Institutes of Health and the Arizona Commerce Authority / WearTech, and memberships in organizations represented by logos, and gives a Phoenix, AZ address at 6161 E Mayo Blvd with contact details. These are the manufacturer's published statements, not FDA findings. [4]
An NSF SBIR awardee page describes a Phase II project titled Point of Care Metabolic Measurement, names Marylaura Thomas as project leader and principal investigator, and states a year founded of 2017 with total raised of $0.003 million, attributing that company data to PitchBook. The page also states that the company offers technology co-developed at educational and medical institutions in Arizona. It does not connect the award to K260613 or to the AMI™ Plasma Cartridge. [7]
What the records do and do not establish
The collection reviewed here contains one linked 510(k) record, with a decision count of one Substantially Equivalent and a record sample of the same single entry; these are counts of the filings assembled as of November 20, 2026, not measures of company sales, total portfolio or safety performance. No recall records appear in the collection. The sources do not establish ownership, a parent company, customers, commercial availability, pricing or independent test results for the AMI™ Plasma Cartridge. [1][6]

